← AI Health Hub

News 2 min read

Leidos and University of Pittsburgh Invest $10 Million in AI for Disease Detection

Leidos and the University of Pittsburgh invest $10 million in AI for disease detection and management. πŸ€–πŸ’°

Yusuf Yesil, MD, MIS

Leidos and University of Pittsburgh Invest $10 Million in AI for Disease Detection

Investment Overview

Leidos, a technology company, is investing $10 million in a collaboration with the University of Pittsburgh to enhance the use of artificial intelligence (AI) for disease detection and management.

Collaboration Goals

This five-year partnership focuses on:

  • Developing AI-powered tools for quicker detection of diseases such as heart disease and cancer.
  • Reducing diagnostic turnaround times to enable earlier and more effective care management.
  • Establishing a research hub at the University of Pittsburgh to advance digital pathology and diagnostics.
Research and Development

The collaboration will involve:

  • Joint research projects to explore new imaging methods and advanced scanning technologies for tissue sample analysis.
  • Improving techniques for analyzing medical images.
Educational Initiatives

The initiative will also include:

  • Educational programs and symposiums.
  • Hands-on internships for students to work alongside Leidos employees.
Leadership Statements

Leidos CEO Tom Bell stated, “Our investment is aimed at using the power of artificial intelligence to speed detection, diagnosis, and treatment of diseases affecting millions annually.” He emphasized the importance of developing future healthcare specialists and expanding care for underserved communities, including veterans.

Broader Context

Recently, Leidos has also partnered with Moveworks, an AI assistant, to enhance government worker efficiency in the U.S., UK, and Australia. Additionally, the company announced a new uncrewed undersea vessel, Sea Dart, to support various missions for the U.S. Navy and commercial clients.

Future Prospects

Leidos aims to leverage this collaboration to deploy AI-powered digital pathology solutions across both public and private healthcare sectors, ultimately leading to the commercialization of innovative healthcare technologies.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment.

Yusuf Yesil, MD, MIS
Yusuf Yesil, MD, MIS

Founder & Medical Doctor at Yesil Science. Clinical Biochemistry Specialist and Health AI researcher focused on clinical decision support, diagnostic AI, and biomedical machine learning.

Follow AI Health Hub